Sobi将在2026年鹿特丹组织细胞协会会议上展示 Gamifant®的临床数据-动脉网

Sobi to present clinical data on Gamifant® at Histiocyte Society 2026 in Rotterdam

CISION 等信源发布 2026-09-24 16:53



可切换为仅中文







STOCKHOLM

斯德哥尔摩

，

Sept. 24, 2026

2026年9月24日

/PRNewswire/ -- Sobi® (STO: SOBI) today announced that new clinical data on Gamifant® (emapalumab) in primary haemophagocytic lymphohistiocytosis (HLH) will be presented at the 2026 Annual Meeting of the Histiocyte Society (HS2026), taking place 26-29 September in Rotterdam, the Netherlands.

/美通社/ -- Sobi®（斯德哥尔摩证券交易所代码：SOBI）今日宣布，将在2026年9月26日至29日于荷兰鹿特丹举行的组织细胞协会2026年年会（HS2026）上公布Gamifant®（emapalumab）治疗原发性噬血细胞性淋巴组织细胞增生症（HLH）的最新临床数据。

The accepted abstracts include a new pooled analysis of pre- and post-transplant survival outcomes across three prospective trials, two encore presentations of analyses in primary HLH, and data from a post-authorisation study in treatment-experienced Chinese patients.

被接受的摘要包括一项对三项前瞻性试验中移植前后生存结局的新汇总分析、两项关于原发性噬血细胞性淋巴组织细胞增生症（HLH）分析的再次报告，以及一项针对经治中国患者的上市后研究数据。

'Sobi is continuing to build the evidence on treatment and transplant outcomes in primary HLH to help people with this rare, life-threatening hyperinflammatory disease. The new pooled-analysis has been selected as one of the ten highest-scoring poster abstracts and nominated for the Robert J. Arceci Prize for Best Poster, which is highly encouraging as it recognises our scientific impact,' said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs and Chief Medical Officer at Sobi..

“Sobi 正在持续积累关于原发性噬血细胞性淋巴组织细胞增多症（HLH）治疗及移植结局的证据，以帮助患有这种罕见且危及生命的过度炎症性疾病的患者。新的汇总分析入选得分最高的十大海报摘要之一，并被提名角逐 Robert J. Arceci 最佳海报奖，这令人备受鼓舞，因为它认可了我们的科学影响力。”Sobi 研发与医学事务负责人兼首席医疗官 Lydia Abad-Franch 博士表示。

Poster presentations

海报展示

Gamifant® (emapalumab)

Gamifant®（依帕利单抗）

Pre- and Post-Transplant Survival with Emapalumab in Primary HLH: Pooled Analysis of Prospective Trials NI-0501-04, NI-0501-05 and NI-0501-09

原发性噬血细胞性淋巴组织细胞增多症患者使用依帕利尤单抗在移植前和移植后的生存率：前瞻性试验NI-0501-04、NI-0501-05和NI-0501-09的汇总分析

Poster Pitch Session, September 29 15:45-17:00 local time

海报展示环节，9月29日 15:45-17:00（当地时间）

Emapalumab Induces Rapid, Durable Responses and Bridging to Curative HSCT in Patients with pHLH

依帕利尤单抗在原发性噬血细胞性淋巴组织细胞增生症（pHLH）患者中诱导快速、持久的反应，并桥接至治愈性造血干细胞移植（HSCT）

Poster session, September 29 15:45-17:00 local time

海报展示环节，9月29日 15:45-17:00（当地时间）

Emapalumab is Associated with Rapid and Sustained Benefits in Primary HLH Subgroups regardless of Previous Treatment or Central Nervous System Involvement

无论既往治疗或中枢神经系统受累情况如何，emapalumab 均与原发性 HLH 亚组的快速且持续的获益相关

Poster session, September 29 15:45-17:00 local time

海报展示环节，9月29日当地时间15:45-17:00

Emapalumab in Treatment-Experienced Primary HLH: Safety, Efficacy, and Transplant Outcomes from the Open-Label, Single-Arm Post-Authorization Study Sobi.EMAPALUMAB-104 in Chinese Patients

依马帕利单抗治疗经治原发性噬血细胞性淋巴组织细胞增生症：中国患者开放标签、单臂上市后研究Sobi.EMAPALUMAB-104的安全性、疗效及移植结局

Poster session, September 29 15:45-17:00 local time

海报展示环节，9月29日 15:45-17:00（当地时间）

About Gamifant® (emapalumab)

关于 Gamifant®（emapalumab）

Gamifant is the only approved anti-interferon gamma (IFNy) monoclonal antibody. Gamifant works by binding to and neutralising interferon gamma (IFNy). When interferon gamma (IFNy) is secreted in an uncontrolled manner, hyperinflammation occurs within the body. Gamifant is indicated for administration through intravenous infusion over one hour..

Gamifant 是唯一获批的抗干扰素γ（IFNγ）单克隆抗体。Gamifant 通过与干扰素γ（IFNγ）结合并使其失活来发挥作用。当干扰素γ（IFNγ）不受控制地分泌时，体内会发生过度炎症反应。Gamifant 的适应症为通过一小时静脉输注给药。

Gamifant is approved in the US for the treatment of adult and paediatric patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. Gamifant is also approved in the US for the treatment of adult and paediatric patients with haemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in known or suspected Still's disease with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS..

Gamifant 在美国获批用于治疗患有原发性噬血细胞性淋巴组织细胞增生症（HLH）且对传统 HLH 疗法难治、复发、进展或不耐受的成人和儿科患者。Gamifant 还在美国获批用于治疗已知或疑似斯蒂尔病（Still's disease）伴发的噬血细胞性淋巴组织细胞增生症（HLH）/巨噬细胞活化综合征（MAS），且对糖皮质激素反应不足或不耐受，或复发性 MAS 的成人和儿科患者。

Sobi®

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 2000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion.

Sobi 是一家全球性生物制药公司，致力于释放突破性创新的潜力，改善罕见病患者的日常生活。Sobi 在欧洲、北美、中东、亚洲和澳大利亚拥有约 2000 名员工。2025 年，公司营收达 280 亿瑞典克朗。

Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at .

Sobi 的股票（STO:SOBI）在斯德哥尔摩纳斯达克交易所上市。更多关于 Sobi 的信息，请访问。

sobi.com

and

和

领英

。

For details on how to contact the Sobi Investor Relations Team, please click

如需了解如何联系 Sobi 投资者关系团队的详细信息，请点击

here

这里